A comparative study of efficacy and safety of febuxostat and allopurinol in pyrazinamide-induced hyperuricemic tubercular patients
| Autor: | M L Aseri, Jameela Tahashildar, S K Luhadia, Arvind Kumar Yadav, Meenu Pichholiya |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Allopurinol antitubercular therapy Antitubercular Agents hyperuricemia Pharmacology Gastroenterology Group B law.invention Gout Suppressants 030207 dermatology & venereal diseases 03 medical and health sciences chemistry.chemical_compound Young Adult 0302 clinical medicine Randomized controlled trial law Internal medicine medicine Humans Pharmacology (medical) Hyperuricemia Adverse effect Aged 030203 arthritis & rheumatology business.industry febuxostat nutritional and metabolic diseases Pyrazinamide Middle Aged medicine.disease Uric Acid Treatment Outcome chemistry Uric acid Female Febuxostat business medicine.drug Research Article |
| Zdroj: | Indian Journal of Pharmacology |
| ISSN: | 1998-3751 |
| Popis: | Objectives: To compare the efficacy and safety of febuxostat and allopurinol in pyrazinamide (PZA)-induced hyperuricemia in patients taking antitubercular therapy (ATT). Methods: This randomized controlled study was conducted at a tertiary care teaching institute of Rajasthan in all the sputum-positive tubercular patients aged between 18 and 65 years of either sex. Serum uric acid level was monitored at 0 th , 2 nd , 4 th , 6 th , and 8 th week of ATT. Patients whose uric acid level was found to be increased at 2 nd week were finally recruited in the study. Ninety patients who developed hyperuricemia due to ATT were divided randomly into three groups (Group A - febuxostat, Group B - allopurinol, and Group C - control) of thirty patients each. Mean serum uric acid levels were calculated at all the weeks in all the groups, and serum uric acid levels were compared by applying student's t-test and ANOVA. Results: Mean serum uric acid level decreased from 10.698 mg/dl (at 2 nd week) to 7.846 mg/dl (at 8 th week) in Group A and from 11.34 mg/dl (at 2 nd week) to 7.280 mg/dl (at 8 th week) in Group B. Numbers of adverse events encountered across both the treatment groups were same with both the drugs. Conclusion: Allopurinol and febuxostat were equally efficacious in lowering PZA induced raised serum uric acid level in tubercular patients, and it was possible to continue ATT without withdrawing PZA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|